Background glaucoma Shape Background glaucoma Shape Background glaucoma Shape
Grants > Complement-Targeted Therapy to Restrict Glaucoma Progression Updated On: Ene. 23, 2025
National Glaucoma Research Grant

Complement-Targeted Therapy to Restrict Glaucoma Progression

Predicting Outcomes & Other Treatment Innovations
Alejandra Bosco, PhD

Principal Investigator

Alejandra Bosco, PhD

The University of Utah

Salt Lake City, UT, USA

About the Research Project

Program

National Glaucoma Research

Award Type

Standard

Award Amount

$200,000

Active Dates

July 01, 2019 - June 30, 2022

Grant ID

G2019219

Acknowledgement

Recipient of the Thomas R. Lee Award for Glaucoma Research.

Goals

Glaucoma is a disease that degrades vision over time. In the retina, neurons decline and die, despite the immune responses of supporting glial cells. We have developed a new potential treatment that rebalances immune responses and controls glaucoma in old mice, and will define if it may cure patients by treating several experimental models. Also, we will study how dying or surviving neurons interact with glia in the retina.

Summary

This project will determine whether rebalancing immune activation of complement proteins and microglia via ocular gene therapy is neuroprotective in diverse experimental models of adult-onset glaucoma. Progressive vision loss in glaucoma is the result of gradual neuron decline and death in the retina, which is accompanied by dysregulated glial immune responses. My research focuses on understanding the role and function of microglia in glaucoma, and on developing translatable therapeutic strategies by modulating the actions of microglia.